SCHEMBL1630085

SCHEMBL1630085

O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(OC(F)F)cc1)N1CCCC1c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
DAGLB Q8NCG7 2/20 0.40
DAGLA Q9Y4D2 2/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
RORC P51449 1/20 0.39
MAPT P10636 6/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
TP53 P04637 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
TRPA1 O75762 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629267 0.92 CRHBP (0.47) CRHBPCRHR2DAGLBDAGLAPSEN1
SCHEMBL1630026 0.91 CRHBP (0.49) CRHBPCRHR2PSEN1PSEN2APH1B
SCHEMBL1629109 0.91 CRHBP (0.49) CRHBPCRHR2PSEN1PSEN2APH1B
SCHEMBL1629094 0.90 CRHBP (0.52) CRHBPCRHR2MAPTLMNATP53
SCHEMBL1630715 0.88 CRHBP (0.45) CRHBPCRHR2PSEN1PSEN2APH1B
SCHEMBL1921822 0.88 MDM4 (0.40) CRHBPCRHR2DAGLBDAGLAPSEN1
SCHEMBL1632105 0.87 CRHBP (0.56) CRHBPCRHR2MAPTLMNATP53
SCHEMBL1630727 0.87 CRHBP (0.48) CRHBPCRHR2RORCMAPTLMNA
SCHEMBL3422507 0.87 CRHBP (0.51) CRHBPCRHR2PSEN1PSEN2APH1B
SCHEMBL1630642 0.87 CRHBP (0.51) CRHBPCRHR2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPSR1 CRHBP 170/4885CRHR2 14/4885DAGLB 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.